Phenobarbital
- Atc Codes:N03AA02
- CAS Codes:50-06-6#57-30-7
- PHARMGKB ID:50-06-6#57-30-7
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Gardenal; Bulgaria: Phenobarbital; Cyprus: Pevalon; Denmark: Fenemal; Estonia: Phenaemal; France: Alepsal, Aparoxal, Gardenal, Kaneuron, Phenobarbital; Germany: Luminal, Luminaletten, Phenaemal, Phenaemaletten, Phenobarbital; Greece: Antiasthman, Atrium, Barbitan, Bellalumine, Bellergal, Cuorosan, Diphenal, Donnatal, Dyspneine, Etaphylline, Gardenal, Kaneuron, Lumidrops, Luminal, Novalumine, Respiren, Seda Nitro Mack, Sedanitrat, Segontin, Theophylline; Hungary: Sevenal, Sevenaletta; Ireland: Phenobarbital; Italy: Fenoba, Gardenale, Luminale; Luxembourg: Epipropane, Gardenal; Netherlands: Fenobarbital; Poland: Luminalum; Portugal: Bialminal, Fenobarbital, Luminal, Luminaletas; Romania: Fenobarbital; Slovakia: Luminal, Phenaemal, Phenaemaletten; Spain: Gardenal, Luminal, Luminaletas, Redutona; Sweden: Fenemal; UK: Phenobarbital.
North America
Canada: Phenobarbital.
Latin America
Argentina: Alepsal, Fenobarbital, Gardenal, Luminal, Luminaletas; Brazil: Barbitron-Fenobarbital, Carbital, Edhanol, Fenobarbital, Fenocris, Garbital, Gardenal, Unifenobarb; Mexico: Alepsal, Fenobarbital.
Asia
Japan: Lupial, Phenobal, Phenobarbital, Wakobital.
Drug combinations
Phenobarbital and Phenytoin
Phenobarbital, Atropine, and Ergotamine
Phenobarbital, Acetaminophen, Caffeine, Codeine, and Dipyrone
Chemistry
Phenobarbital: C~12~H~12~N~2~O~3~. Mw: 232.24. (1) 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-; (2) 5-Ethyl-5-phenylbarbituric acid. CAS-50-06-6.
Phenobarbital Sodium: C~12~H~11~N~2~NaO~3~. Mw: 254.22. Sodium 5-ethyl-5-phenylbarbiturate. CAS-57-30-7.
Pharmacologic Category
Anticonvulsants; Barbiturates. Anxiolytics, Sedatives, and Hypnotics; Barbiturates. (ATC-Code: N03AA02).
Mechanism of action
Long-acting barbiturate with sedative, hypnotic, and anticonvulsant properties. Barbiturates depress sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit anticonvulsant activity. They also produce dose-dependent respiratory depression.
Therapeutic use
Management of generalized tonic-clonic (grand mal) and partial seizures. Sedative.
Pregnancy and lactiation implications
Crosses placenta. Cardiac defect reported. Hemorrhagic disease of newborn due to fetal vitamin K depletion may occur. May induce maternal folic acid deficiency. Withdrawal symptoms observed in infant following delivery. Use with caution during lactation (sedation reported in nursing infants. Infantile spasms may occur after weaning from breast milk).
Unlabeled use
Febrile seizures in children. May also be used for prevention and treatment of neonatal hyperbilirubinemia and lowering of bilirubin in chronic cholestasis. Neonatal seizures. Management of sedative/hypnotic withdrawal.
Contraindications
Hypersensitivity to barbiturates or any component of the formulation. Marked hepatic impairment. Dyspnea or airway obstruction. Porphyria (manifest and latent). Intra-arterial administration, subcutaneous administration (not recommended). Use in history of sedative/hypnotic addiction not recommended. Nephritic patients (large doses).
Warnings and precautions
May cause CNS depression. May cause hypotension, particularly when administered intravenously (use with caution in hemodynamically unstable patients (hypotension or shock)). May cause paradoxical responses, including agitation and hyperactivity, particularly in acute pain and pediatric patients. May cause respiratory depression, particularly when administered intravenously (use with caution in respiratory disease). Use with caution in depression or suicidal tendencies, in hepatic or renal impairment, and in hypoadrenalism. Potential for drug dependency exists (use with caution in history of drug abuse). Tolerance, psychological and physical dependence may occur with prolonged use. Effects with other sedative drugs or ethanol may be potentiated. Use with caution in debilitated patients, in the elderly (not recommended as a sedative), in children (associated with cognitive deficits). Intra-arterial administration may cause reactions ranging from transient pain to gangrene, and is contraindicated. Subcutaneous administration may cause tissue irritation (e.g. redness, tenderness, necrosis); not recommended. Should not be administered in acute pain. Anticonvulsants should not be discontinued abruptly. Injectable solutions contain propylene glycol.